DEVELOP AND PRODUCE DOSAGE FORMS OF ANTI-AIDS AGENTS

该项目的主要目标是开发和生产 有前途的新药的药学上可接受的肠胃外剂型 具有抗艾滋病活性。 通过药物选择选择的一些药物 委员会将被指定负责注射剂的开发和生产 产品。 最初，第一阶段的批量大小预计较小， 二试。 然而，III/IV 期升级至大批量 预计将进行试验和 C 组分配。 估计这 项目必须准备每年生产数百万个剂量单位。

The primary objective of this project is to develop and produce pharmaceutically acceptable parenteral dosage forms of promising new agents with anti-AIDS activity. Some agents selected by a Drug Selection Committee will be assigned for development and production as a parenteral product. Initially, the batch sizes are expected to be small phase I and II trials. However, escalation to large batch sizes for phase III/IV trials and Group C distribution is anticipated. It is estimated that this project must be prepared to produce several million dosage units each year.